| European Federation of Internal Medicine

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News

Type: News Feed

Draft reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in animals in the European Union: development of resistance and impact on public and animal health - Revision 1

Submitted by Anonymous (not verified) on 24 April 2026 - 9:15

Draft reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in animals in the European Union: development of resistance and impact on public and animal health - Revision 1

Read more about Draft reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in animals in the European Union: development of resistance and impact on public and animal health - Revision 1

Use of macrolides, lincosamides and streptogramins (MLS) in animals in the European Union: development of resistance and impact on public and animal health - Scientific guideline

Submitted by Anonymous (not verified) on 24 April 2026 - 9:14

Use of macrolides, lincosamides and streptogramins (MLS) in animals in the European Union: development of resistance and impact on public and animal health - Scientific guideline

Read more about Use of macrolides, lincosamides and streptogramins (MLS) in animals in the European Union: development of resistance and impact on public and animal health - Scientific guideline

Human medicines European public assessment report (EPAR): Vysribli (previously Denosumab Intas), Vysribli, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 24 April 2026 - 9:10

Human medicines European public assessment report (EPAR): Vysribli (previously Denosumab Intas), Vysribli, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Vysribli (previously Denosumab Intas), Vysribli, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, risankizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0497/2022

Submitted by Anonymous (not verified) on 23 April 2026 - 16:22

Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, risankizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0497/2022

Read more about Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, risankizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0497/2022

Human medicines European public assessment report (EPAR): Terrosa, teriparatide, Date of authorisation: 04/01/2017, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 23 April 2026 - 16:05

Human medicines European public assessment report (EPAR): Terrosa, teriparatide, Date of authorisation: 04/01/2017, Revision: 8, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Terrosa, teriparatide, Date of authorisation: 04/01/2017, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Kinpeygo, budesonide, Date of authorisation: 15/07/2022, Revision: 12, Status: Authorised

Submitted by Anonymous (not verified) on 23 April 2026 - 16:02

Human medicines European public assessment report (EPAR): Kinpeygo, budesonide, Date of authorisation: 15/07/2022, Revision: 12, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Kinpeygo, budesonide, Date of authorisation: 15/07/2022, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Jayempi, azathioprine, Date of authorisation: 21/06/2021, Revision: 9, Status: Authorised

Submitted by Anonymous (not verified) on 23 April 2026 - 15:48

Human medicines European public assessment report (EPAR): Jayempi, azathioprine, Date of authorisation: 21/06/2021, Revision: 9, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Jayempi, azathioprine, Date of authorisation: 21/06/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Aptivus, tipranavir, Date of authorisation: 25/10/2005, Revision: 44, Status: Authorised

Submitted by Anonymous (not verified) on 23 April 2026 - 15:32

Human medicines European public assessment report (EPAR): Aptivus, tipranavir, Date of authorisation: 25/10/2005, Revision: 44, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Aptivus, tipranavir, Date of authorisation: 25/10/2005, Revision: 44, Status: Authorised

Human medicines European public assessment report (EPAR): Praxbind, idarucizumab, Date of authorisation: 20/11/2015, Revision: 14, Status: Authorised

Submitted by Anonymous (not verified) on 23 April 2026 - 15:28

Human medicines European public assessment report (EPAR): Praxbind, idarucizumab, Date of authorisation: 20/11/2015, Revision: 14, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Praxbind, idarucizumab, Date of authorisation: 20/11/2015, Revision: 14, Status: Authorised

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Draft reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in animals in the European Union: development of resistance and impact on public and animal health - Revision 1

Use of macrolides, lincosamides and streptogramins (MLS) in animals in the European Union: development of resistance and impact on public and animal health - Scientific guideline

Human medicines European public assessment report (EPAR): Vysribli (previously Denosumab Intas), Vysribli, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, risankizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0497/2022

Human medicines European public assessment report (EPAR): Terrosa, teriparatide, Date of authorisation: 04/01/2017, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Kinpeygo, budesonide, Date of authorisation: 15/07/2022, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Jayempi, azathioprine, Date of authorisation: 21/06/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Aptivus, tipranavir, Date of authorisation: 25/10/2005, Revision: 44, Status: Authorised

Human medicines European public assessment report (EPAR): Praxbind, idarucizumab, Date of authorisation: 20/11/2015, Revision: 14, Status: Authorised

Newsletters

Latest Newsletters

You are here

Newsletters

Latest Newsletters